Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal Microbiota Transplantation (The Chinese University of Hong Kong)
- Development stage
- Unknown
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplantation (FMT) is a therapeutic procedure involving the transfer of fecal matter from a healthy donor into the gastrointestinal tract of a recipient to restore a healthy microbial balance. This specific application, investigated by the Chinese University of Hong Kong, focuses on the eradication of intestinal colonization by multidrug-resistant organisms (MDROs), specifically carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant Enterococcus (VRE). The mechanism of action relies on the restoration of gut microbiota diversity, which provides colonization resistance through competitive exclusion, production of antimicrobial metabolites, and modulation of the host's mucosal immunity. In the context of the pilot study conducted by the Chinese University of Hong Kong, the FMT infusion is administered via esophagogastroduodenoscopy (OGD) to target the upper gastrointestinal tract.
- Brand names
- RebyotaVowst
- Other names
- FMTFecal Microbiota TransplantFecal Bacteriotherapy
Beyond the preview
Go deeper on Fecal Microbiota Transplantation (The Chinese University of Hong Kong).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal Microbiota Transplantation (The Chinese University of Hong Kong).